Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

Alkermes Inc. plc (NASDAQ:ALKS) stock is trading higher on Tuesday following the announcement of positive topline results from the REVITALYZ phase 3 study evaluating LUMRYZ extended-release oral suspension for excessive daytime sleepiness associated with idiopathic hypersomnia.

Benzinga • May 12, 2026

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ℠ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ® (sodium oxybate) extended-release oral suspension in adults with idiopathic hypersomnia (IH). LUMRYZ met the study's primary endpoint, demonstrating statistically significant improvements in excessive daytime sleepiness compared to placebo as measured by t.

Business Wire • May 12, 2026

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Alkermes (NASDAQ:ALKS) reported upbeat results for the first quarter on Tuesday.

Benzinga • May 6, 2026

Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises

ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.

Zacks Investment Research • May 6, 2026

Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company

Alkermes is transitioning into an integrated neuroscience and sleep medicine company, highlighted by the Avadel acquisition and LUMRYZ integration. Q1 2026 results show proprietary product sales rising to $338.1M, with LUMRYZ contributing $39.5M post-acquisition; adjusted EBITDA improved to $80.3M. Management projects 2026 revenues of $1.73–$1.84B, with four commercial products each targeting over $300M in annual net sales.

Seeking Alpha • May 6, 2026

Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript

Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 5, 2026

Alkermes plc Reports First Quarter 2026 Financial Results

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today to discuss these financial results and expectations and prov.

Business Wire • May 5, 2026

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • May 5, 2026

Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates

Alkermes (ALKS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to earnings of $0.13 per share a year ago.

Zacks Investment Research • May 5, 2026

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 28, 2026